We conclude that testing for the TS-3'UTR 6-bp deletion and XPD polymorphisms might be a candidate pharmacogenomic factors to be explored in the future larger scale study to identify the gastric cancer patients who might benefit from 5-FU based first line chemotherapy. This evidence concerns the gene TYMS and gastric cancer.